Gene and cell therapies (GCTs) can target the kidney to treat congenital, acute or chronic diseases affecting this organ.

Microsatellite instability (MSI), which results from defects in the DNA mismatch repair system, is an important biomarker in colorectal cancer. While the MSI-high (MSI-H) status predicts response to ...

Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to ...

A pair of studies published in Diabetologia demonstrate that use of continuous glucose monitors (CGMs) reduces ...

The U.S. Centers for Medicare & Medicaid Services reported a request for information for a modernized digital health ...

Current therapies for chronic hepatitis B virus (HBV) infection can effectively suppress viral replication but do not achieve ...

Just two months after Inozyme Pharma Inc. cut its workforce by 25% and prioritized activities to focus on a BLA filing for INZ-701 for ENPP1 deficiency, interim phase III data from its Energy 3 trial ...

Royal Philips NV unveiled its Future Health Index report for 2025, and it reveals the widening trust gap between health care professionals and patients concerning the adoption of AI in health care.

Using a customized gene editing therapy, researchers at the Children’s Hospital of Philadelphia have reported success in treating an infant with a severe metabolic disorder. Kiran Musunuru, Barry J.

Researchers at the China Pharmaceutical University have developed a series of highly active receptor-interacting protein kinase 1 (RIPK1) inhibitors with potent anti-inflammatory activity. RIPK1 is a ...

Pancreatic cancer is one of the deadliest malignancies, with a 5-year overall survival rate of only 13%. Earlier studies demonstrated that the Lister strain of oncolytic vaccinia virus (VVL) is ...

Abcellera Biologics Inc. has received a no objection letter from Health Canada authorizing its clinical trial application (CTA) for ABCL-635.